TORONTO -- Blood tests for Alzheimer's disease biomarkers can be used clinically -- and can replace expensive brain scans and ...

Genentech, a member of Roche (RHHBY), announced that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s ...

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% ...

Without the receptor, ADGRG1, the microglia barely nibbled on the toxic protein. Using a mouse model of Alzheimer’s disease, the researchers observed how the loss of ADGRG1 led to the rapid buildup of ...

Shares in nuclear medicine play Clarity Pharmaceuticals have surged up to 12% after the company's swift $203 million raising.

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

DelveInsight's TYK2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Following a period of relative dormancy, research and development in the Alzheimer’s disease space is booming. And mounting attention, both in the development of disease modifying therapies (DMTs) and ...

Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...

The Global Neurodegeneration Proteomics Consortium (GNPC) has published a series of research papers detailing their efforts to identify patterns in neurodegenerative disease. Sifting through roughly ...

Researchers are investigating blood-based biomarkers like pTau217 for Alzheimer’s detection, offering a less invasive ...